Nabriva Therapeutics AG - Product Pipeline Review 2015 offers “Nabriva Therapeutics AG – Product Pipeline Review – 2015”global research report on its store.

This report provides comprehensive information on the current therapeutic developmental pipeline of Nabriva Therapeutics AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

The Complete report is available at .

Scope of The Report:

- The report provides brief overview of Nabriva Therapeutics AG including business description, key information and facts, and its locations and subsidiaries

- The report reviews current pipeline of Nabriva Therapeutics AG’s human therapeutic division and enlists all their major and minor projects

- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones

- Special feature on out-licensed and partnered product portfolio

- The report summarizes all the dormant and discontinued pipeline projects

- Latest company statement

- Latest news and deals relating to the Nabriva Therapeutics AG’s pipeline products

Reasons to Buy This Report:

- Evaluate Nabriva Therapeutics AG’s strategic position with total access to detailed information on its product pipeline

- Assess the growth potential of Nabriva Therapeutics AG in its therapy areas of focus

- Identify new drug targets and therapeutic classes in the Nabriva Therapeutics AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

- Develop strategic initiatives by understanding the focus areas of Nabriva Therapeutics AG and exploit collaboration and partnership opportunities

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Nabriva Therapeutics AG

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Explore the dormant and discontinued projects of Nabriva Therapeutics AG and identify potential opportunities in those areas

- Avoid Intellectual Property Rights related issues

Order a purchase copy of this report at .

Table of Content for “Nabriva Therapeutics AG – Product Pipeline Review – 2015” research report includes:

List of Tables

Nabriva Therapeutics AG, Key Information 4

Nabriva Therapeutics AG, Key Facts 4

Nabriva Therapeutics AG - Pipeline by Indication, 2015 7

Nabriva Therapeutics AG - Pipeline by Stage of Development, 2015 8

Nabriva Therapeutics AG - Monotherapy Products in Pipeline, 2015 9

Nabriva Therapeutics AG - Phase II, 2015 10

Nabriva Therapeutics AG - Phase I, 2015 11

Nabriva Therapeutics AG - Preclinical, 2015 12

Nabriva Therapeutics AG - Pipeline by Target, 2015 17

Nabriva Therapeutics AG - Pipeline by Route of Administration, 2015 18

Nabriva Therapeutics AG - Pipeline by Molecule Type, 2015 19

Nabriva Therapeutics AG - Pipeline Products by Mechanism of Action, 2015 20

Nabriva Therapeutics AG - Recent Pipeline Updates, 2015 21

Nabriva Therapeutics AG - Dormant Developmental Projects,2015 23

Nabriva Therapeutics AG, Subsidiaries 24

Priced at US $1500 for a single user PDF, a discount on this research report can be requested at .

About Us:

RnR Market Research library offers syndicated reports by market research publishers from across the globe. We help you find the most relevant business intelligence from ready-to-buy syndicated market research studies. Not limited to industry reports covering telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, F&B , media and more, RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest. ( .)